{"id":266438,"date":"2026-01-27T12:12:08","date_gmt":"2026-01-27T12:12:08","guid":{"rendered":"https:\/\/www.newsbeep.com\/ie\/266438\/"},"modified":"2026-01-27T12:12:08","modified_gmt":"2026-01-27T12:12:08","slug":"roche-moves-obesity-drug-to-pivotal-trials-after-mid-stage-success","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ie\/266438\/","title":{"rendered":"Roche moves obesity drug to pivotal trials after mid-stage success"},"content":{"rendered":"

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71.<\/p>\n

Roche plans to launch Phase 3 studies of its leading obesity candidate this quarter after reporting Tuesday that the drug led to significant weight loss in a mid-stage trial.\u00a0<\/p>\n

The drug, known as CT-388, led to a placebo-adjusted weight loss of 18.3% after 48 weeks in the Phase 2 trial at the highest dose tested of 24 milligrams, the Swiss pharma said.<\/p>\n

Roche said that patients were still losing weight at the end of the study period. Just under 6% of patients on the treatment dropped out of the trial due to side effects, which Roche said were largely the gastrointestinal symptoms seen broadly with new weight loss treatments, versus 1.3% of those in the placebo group.\u00a0<\/p>\n

STAT+ Exclusive Story<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\"STAT+\"\/<\/p>\n

\t\t\t\t\t
\n\t\t\t\t\t\t\"STAT+\"\/
\n\t\t\t\t\t<\/a><\/p>\n

\t\t\t\tThis article is exclusive to STAT+ subscribers
\n\t\t\t\tUnlock this article \u2014 plus daily coverage and analysis of the pharma industry \u2014 by subscribing to STAT+.<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\t\t\tIndividual plans<\/p>\n

\t\t\t\t\t\tGroup plans<\/p>\n

\t\t\t\tView All Plans<\/a><\/p>\n

\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n

\t\t\t\t\tSubscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at…\n","protected":false},"author":2,"featured_media":266439,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[10818,103,397,396,61,60,4369,1691,2369],"class_list":{"0":"post-266438","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-drug-development","9":"tag-health","10":"tag-health-care","11":"tag-healthcare","12":"tag-ie","13":"tag-ireland","14":"tag-obesity","15":"tag-pharmaceuticals","16":"tag-stat"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/266438","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=266438"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/266438\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/266439"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=266438"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=266438"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=266438"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}